ArticleNeurology. Clinical practice2025
Diagnostic Accuracy of Oligoclonal Bands for CNS Autoimmune Disorders in Acutely Ill Adults.
Article in Neurology. Clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Intrathecal antibody synthesis - Reiber method revisited.BMC neurology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: The presence of oligoclonal bands (OCBs) indicates an augmented immune response within the CNS and is integral to the diagnosis of multiple sclerosis (MS). Expert consensus panels recommend OCB testing for conditions other than MS, despite limited data to suggest diagnostic value. Our objectives were to evaluate the spectrum of disease etiologies associated with OCBs and determine the accuracy of OCBs in identifying autoimmune disorders affecting the CNS. Methods: This is a retrospective, observational, single health system study that captured all patients in acute care settings who underwent OCB testing from January 1, 2018, through December 31, 2020. Patient diagnoses and diagnostic categories were adjudicated by clinicians. Test accuracy characteristics to detect CNS autoimmune disorders were computed by comparing 2 or more OCBs as a positive index test against target disease etiologies as reference standards. Results: OCB testing was performed across all etiologies in 926 patients; 78 patients had MS, and 148 had CNS autoimmune disorders not related to MS. Oligoclonal bands exhibited high sensitivity for MS but low sensitivity and low predictive power for other CNS autoimmune disorders. Discussion: In contrast to their diagnostic accuracy in MS, OCBs exhibited limited discriminatory power in the detection of other autoimmune disorders affecting the CNS. Beyond suspected MS, OCBs should not be relied on as an accurate diagnostic tool because a positive result can manifest in an array of neurologic diseases and a negative result does not exclude an autoimmune etiology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.